We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

595 hedge funds and large institutions have $30B invested in Alexion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 218 increasing their positions, 214 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 45

27% more call options, than puts

Call options by funds: $551M | Put options by funds: $435M

15% more capital invested

Capital invested by funds: $26B → $30B (+$4.01B)

6% more funds holding

Funds holding: 559 → 595 (+36)

2% more repeat investments, than reductions

Existing positions increased: 218 | Existing positions reduced: 214

0% more funds holding in top 10

Funds holding in top 10: 19 → 19 (0)

Holders
595
Holders Change
+36
Holders Change %
+6.44%
% of All Funds
14.83%
Holding in Top 10
19
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.47%
New
88
Increased
218
Reduced
214
Closed
45
Calls
$551M
Puts
$435M
Net Calls
+$117M
Net Calls Change
-$98.3M

Top Buyers

1
Jennison Associates
Jennison Associates
New York
+$636M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$118M
3
AQR Capital Management
AQR Capital Management
Connecticut
+$83.6M
4
UBS AM
UBS AM
Illinois
+$69.1M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$67.9M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$328M
2
Sands Capital Management
Sands Capital Management
Virginia
-$213M
3
Goldman Sachs
Goldman Sachs
New York
-$183M
4
State Street
State Street
Massachusetts
-$82.3M
5
BlackRock
BlackRock
New York
-$77.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
CLM
51
ClearBridge LLC (Maryland)
Maryland
$88.5M -$26.7M -196,158 -24%
Sumitomo Mitsui Trust Group
52
Sumitomo Mitsui Trust Group
Japan
$87.9M -$1.05M -7,717 -1%
TA
53
Teachers Advisors
New York
$86.7M -$51.4M -378,073 -38%
LCOV
54
London Company of Virginia
Virginia
$84.6M -$2.38M -17,554 -3%
Federated Hermes
55
Federated Hermes
Pennsylvania
$80M -$8.26M -60,816 -10%
New York State Common Retirement Fund
56
New York State Common Retirement Fund
New York
$79.5M – – –
SO
57
STRS Ohio
Ohio
$78.3M +$3.36M +24,756 +5%
BM
58
Bridger Management
New York
$77.9M +$47.4M +349,114 +169%
SIG
59
Senator Investment Group
New York
$77.2M -$17M -125,000 -19%
PC
60
Polar Capital
United Kingdom
$74.8M +$50M +368,288 +224%
AllianceBernstein
61
AllianceBernstein
Tennessee
$72.3M -$6.73M -49,522 -9%
Alkeon Capital Management
62
Alkeon Capital Management
New York
$70.1M +$67.9M +500,000 New
California Public Employees Retirement System
63
California Public Employees Retirement System
California
$65M +$2.12M +15,588 +3%
RSCM
64
Rock Springs Capital Management
Maryland
$65M – – –
UBS Group
65
UBS Group
Switzerland
$64.6M +$8.09M +59,551 +15%
Westfield Capital Management
66
Westfield Capital Management
Massachusetts
$63.6M +$16.6M +121,897 +37%
GC
67
Guggenheim Capital
Illinois
$62.8M -$14.6M -107,539 -19%
Mitsubishi UFJ Trust & Banking
68
Mitsubishi UFJ Trust & Banking
Japan
$62.8M -$725K -5,339 -1%
MVP
69
Miller Value Partners
Florida
$62.3M -$856K -6,300 -1%
Renaissance Technologies
70
Renaissance Technologies
New York
$62M +$31.2M +229,900 +108%
TD Asset Management
71
TD Asset Management
Ontario, Canada
$59.8M +$3.96M +29,138 +7%
CS
72
Credit Suisse
Switzerland
$58.8M -$12.2M -89,599 -18%
Canada Pension Plan Investment Board
73
Canada Pension Plan Investment Board
Ontario, Canada
$55.1M +$5.56M +40,900 +12%
RhumbLine Advisers
74
RhumbLine Advisers
Massachusetts
$54.5M -$549K -4,040 -1%
Prudential Financial
75
Prudential Financial
New Jersey
$54.5M +$92.4K +680 +0.2%
1 2
3
4 5

ALXN Hedge Fund Activity: Q3 2017 in Review

595 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2017, worth a combined $30B — up 15% from $26B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new ALXN positions and 45 closed out — a net gain of 43 holders — while 218 added to existing stakes and 214 trimmed.

The largest buyer was Jennison Associates, adding an estimated $636M. The largest seller was Fidelity Investments, cutting an estimated $328M.

  • 595 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2017, up from 559 in Q2 2017.
  • Funds reported $30B of Alexion Pharmaceuticals stock for Q3 2017, up 15% quarter-over-quarter.
  • 88 funds opened new Alexion Pharmaceuticals positions in Q3 2017 and 45 closed out, a net change of +43 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2017 was Jennison Associates, an estimated $636M added.
  • The largest Alexion Pharmaceuticals seller in Q3 2017 was Fidelity Investments, an estimated $328M sold.

Based on aggregated 13F filings for Q3 2017.